myMatrixx Position on COVID-19 Vaccination and Workers' Compensation Coverage

Posted on February 20, 2021 by myMatrixx
myMatrixx COVID-19 Vaccination Position Paper

The continuing rollout of the COVID-19 vaccine, while welcome, brings questions regarding coverage that are new to the workers’ compensation pharmaceuticals field. This is an emerging and evolving topic that the entire myMatrixx team is keeping a close eye on. To provide essential information about the vaccine, drug therapy in general, and the most up-to-date formulary considerations, we recently released a whitepaper sharing the myMatrixx position on Position Paper regarding COVID-19 Vaccination and Coverage under Workers’ Compensation.

The paper provides an overview of the cost of the vaccine, associated administration fees, reimbursement guidelines, formulary considerations and efficacy rates, particularly as they may apply to the workforce. There are also sections covering herd immunity, the emergence of new COVID-19 strains and vaccine availability as these continue to be significant areas of concern around the pandemic. You can view the full position paper and get the latest updates on our COVID-19 resources page

Read Position Paper 

COVID-19 Resources